To Date, More Than $25 Million Awarded to 11 Start-Ups and 16 Academic Institutions
$3 Million for Round Three Awardees Focusing on Rapid and Point-of-Care Diagnostics and Surveillance Tools
Keeping New York State at the Forefront of Infectious Disease Discovery and Development
Governor Kathy Hochul today announced the third round of awardees for the $40 Million New York State Biodefense Commercialization Fund. The program was created to accelerate the development and commercialization of life science innovations that address serious infectious disease threats, including COVID-19 and its variants, while also creating jobs and encouraging continued growth across New York’s expanding life science industry. Upon approval by the Empire State Development Board of Directors, four grants will be awarded for this round, representing a combined commitment of more than $3 million.
“To protect the health of New Yorkers and future generations, we are ensuring New York State is a leader in cutting edge infectious disease discovery," Governor Hochul said. "These awards will continue to attract significant jobs and investments so we can continue building the strongest life science ecosystem in the nation.”
Empire State Development President, CEO and Commissioner Hope Knight said, “The Biodefense Commercialization Fund is benefitting the state in numerous ways —smoothing the commercialization pathway for innovative research, adding jobs and investment funding, attracting additional non-dilutive funding, and stimulating growth of our life science ecosystem.”